WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005032558) EXTENDED TRIPHASIC CONTRACEPTIVE REGIMENS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/032558    International Application No.:    PCT/US2004/032497
Publication Date: 14.04.2005 International Filing Date: 30.09.2004
IPC:
A61K 31/565 (2006.01), A61K 31/57 (2006.01)
Applicants: JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 BEERSE (BE) (For All Designated States Except US).
LAGUARDIA, Katherine D. [US/US]; (US) (For US Only)
Inventors: LAGUARDIA, Katherine D.; (US)
Agent: JOHNSON, Philip, S.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US)
Priority Data:
60/507,536 01.10.2003 US
Title (EN) EXTENDED TRIPHASIC CONTRACEPTIVE REGIMENS
(FR) REGIMES CONTRACEPTIFS TRIPHASIQUES ETENDUS
Abstract: front page image
(EN)An extended triphasic oral contraceptive regimen is disclosed. According to the disclosed regimen, a combination of an estrogen and a progestin is administered for at least 42 consecutive days followed by a hormone-free period of from 4 to 8 days. The estrogen and progestin are administered in a contraceptively effective daily dosage for a sequence of at least two cycles of at least 21 days, wherein the estrogen dosage remains constant over each cycle and the progestin dosage increases in three phases over each cycle.
(FR)L'invention concerne un régime contraceptif oral triphasique étendu. Selon ce régime, une combinaison d'un oestrogène et d'une progestine est administrée pendant au moins 42 jours consécutifs suivis d'une période sans hormones de 4 à 8 jours. L'oestrogène et la progestine sont administrés en dose quotidienne efficace du point de vue contraceptif pour une séquence d'au moins deux cycles d'au moins 21 jours, la dose d'oestrogène restant constante dans chaque cycle et la dose de progestine augmentant en trois phases dans chaque cycle.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)